Our hope is that, by expanding the scope of investigation, BRAFV600E mCRC will one day become like HER2-positive breast cancer, where what was once a poor-prognosis subtype with few treatment choices has been transformed into an opportunity to receive effective targeted therapy options. This evidence concerns the gene ERBB2 and breast cancer.